FDA Drug Recalls

Recalls / Class II

Class IID-0021-2026

Product

Viorele, Desogestrel and Ethinyl Estradiol, USP, 0.15 mg/ 0.02 mg and Ethinyl Estradiol Tablets, USP, 0.01 mg, 3 Blisters each containing 28 Tablets, Rx only, 28 day Regimen, Manufactured by: Glenmark Pharmaceuticals Limited, Colvale-Bardez, Goa 403513, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA., Mahwah, NJ, 07430, NDC 68462-318-29.

Brand name
Viorele
Generic name
Desogestrel And Ethinyl Estradiol And Ethinyl Estradiol
NDC
68462-318
FDA application
ANDA091346
Affected lot / code info
Batch number 20230733, Exp Date: October 2025

Why it was recalled

Failed Impurities/Degradation Specifications

Recalling firm

Firm
Glenmark Pharmaceuticals Inc., USA
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
750 Corporate Dr, Mahwah, New Jersey 07430-2009

Distribution

Quantity
26,928 packs
Distribution pattern
US Nationwide.

Timeline

Recall initiated
2025-09-03
FDA classified
2025-10-15
Posted by FDA
2025-10-22
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0021-2026. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Viorele · FDA Drug Recalls